WO2021019448A1 - Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine - Google Patents

Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine Download PDF

Info

Publication number
WO2021019448A1
WO2021019448A1 PCT/IB2020/057128 IB2020057128W WO2021019448A1 WO 2021019448 A1 WO2021019448 A1 WO 2021019448A1 IB 2020057128 W IB2020057128 W IB 2020057128W WO 2021019448 A1 WO2021019448 A1 WO 2021019448A1
Authority
WO
WIPO (PCT)
Prior art keywords
tafamidis
formula
acid
group
salt
Prior art date
Application number
PCT/IB2020/057128
Other languages
English (en)
Inventor
Kura Rathnakar Reddy
Kesireddy SUBHASH CHANDER REDDY
Mule SIVANAGI REDDY
Original Assignee
Honour (R&D)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honour (R&D) filed Critical Honour (R&D)
Publication of WO2021019448A1 publication Critical patent/WO2021019448A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present invention relates to process for the preparation of Tafamidis Meglumine as well polymorphic form of Tafamidis.
  • Tafamidis and Tafamidis Meglumine represented by the following structures Formula I and Formula IA that contains Tafamidis as active moiety chemically known as 2-(3,5- dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid.
  • Formula I and Formula IA that contains Tafamidis as active moiety chemically known as 2-(3,5- dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid.
  • Tafamidis has been approved in different compositions using Tafamidis and Tafamidis Meglumine salt, whereas in Europe it’s approved using Tafamidis Meglumine salt and are marketed under the trade name VYNDAMAXTM and VYNDAQEL ® .
  • Tafamidis and its salts are approved and indicated for Transthyretin stabilizers for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
  • the recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily, or VYNDAMAX 61 mg (one 61 -mg tafamidis capsule) orally once daily.
  • US 7,214,695 discloses 6-Carboxy-2-(3,5-dihalophenyl)-benzoxazole compounds or pharmaceutically acceptable salts thereof.
  • US’ 695 disclose the process for the preparation of Tafamidis as follows:
  • polymorphism is defined as“the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice. Thus, in the strict sense, polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules”. Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning calorimetry (DSC) and Infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning calorimetry
  • IR Infrared spectrometry
  • Tafamidis polymorphs Form 1 has been prepared from Isopropanol
  • Form 2 has been prepared by evaporating tetrahydrofuran solution of Form 1
  • Form 4 has been prepared by heating suspension of Form 1 in tetrahydrofuran and filtering the hot solution in to toluene and then storing in freezer overnight
  • Form 6 has been prepared by heating suspension of Form 1 in tetrahydrofuran, adding dimethylacetamide and the solution resulted was transferred in to dichloromethane in chilled ice/water bath and then by vacuum filtration and drying.
  • Tafamidis and Tafamidis meglumine exits in different polymorphic forms which differ in the physicochemical properties like dissolution and solubility, chemical and physical stability, flowability and hygroscopicity as well as preparation thereof.
  • polymorphs and salts which are stable and suitable for pharmaceutical composition.
  • the prior art process involves the isolation of Tafamidis free base, which is time consuming and also not suitable for large scale production of Tafamidis meglumine.
  • the present inventors have found that in addition to the meglumine salt disclosed there are other salts which can be more easily isolated as crystalline forms and also has enhanced the purity of final active pharmaceutical ingredient.
  • the present inventors have now found a process for the preparation of Tafamidis meglumine which is convenient, cheap, industrially feasible and economical.
  • the objective of the present invention is to provide a process for the preparation of Tafamidis meglumine by not isolating Tafamidis free acid which is commercially and industrially feasible.
  • Another objective of the present invention is to provide Tafamidis solid dispersion and process for the preparation thereof.
  • the present invention relates to a process for the preparation of Tafamidis meglumine compound of Formula IA,
  • the present invention relates to Tafamidis solid dispersion, in combination with a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus.
  • the present invention relates to process for the preparation of Tafamidis solid dispersion which comprises:
  • a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus in a solvent at a suitable temperature;
  • the present invention relates to process for the preparation of Tafamidis solid dispersion which comprises:
  • the present invention relates to process for the preparation of Tafamidis salt of Formula IB which comprises: a. cyclizing the compound of Formula IV
  • organic or inorganic base selected from group comprising of alkaline bases, amines in the presence of a solvent
  • the present invention relates to process for the preparation of Tafamidis salt which comprises:
  • organic or inorganic base is selected from group comprising of alkaline bases, amines.
  • the present invention relates to crystalline form of compound of Formula IV which is characterized peaks by Powder X-Ray Diffraction, having the °20 characteristic peaks at 13.5, 15.5, 24.3+ 0.2 degrees.
  • Figure 1 shows powder X-ray diffractogram pattern of compound of Formula IV.
  • Figure 2 shows powder X-ray diffractogram pattern of Tafamidis solid dispersion with Copovidone.
  • Figure 3 shows powder X-ray diffractogram pattern of Tafamidis solid dispersion with HPMC.
  • X-ray powder diffraction spectrum was measured on a Bruker AXS D8 advance X-ray powder diffractometer having a copper radiation. Adequate sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.02 increment and scan speed of 0.2 Sec/Step. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • the present invention relates to a process for the preparation of Tafamidis meglumine compound of Formula IA, wherein the process comprises: cyclizing the compound of Formula IV with acid selected from the group comprising of Methane sulfonic acid, Ethane sulfonic acid, p-Toluene sulfonic acid, Benzene sulfonic acid, Camphor sulfonic acid, D- Camphor sulfonic acid, L- Camphor sulfonic acid, pyridine sulfonic acid, polyphosphoric acid or acid anhydride selected from the group comprising of acetic anhydride, triflic anhydride; adding meglumine; isolating Tafamidis meglumine compound of Formula IA, wherein the process is carried out by not isolating Tafamidis free acid of Formula I.
  • acid selected from the group comprising of Methane sulfonic acid, Ethane sulfonic acid, p-Toluene s
  • the present invention relates to a Tafamidis solid dispersion in combination with a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus which is obtained in the form of crystalline, amorphous or mixture of crystalline and amorphous form.
  • a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus which is obtained in the form of crystalline, amorphous or mixture of crystalline and amorphous form.
  • the present invention relates to process for the preparation of Tafamidis solid dispersion in combination with a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus which comprises: treating Tafamidis free acid of Formula I with a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus in a solvent at suitable temperature; removing the solvent to obtain solid dispersion of Tafamidis in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus
  • the present invention relates to process for the preparation of Tafamidis solid dispersion in combination with a pharmaceutically acceptable carrier selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus which comprises: desaltification of Tafamidis salt of Formula IB by adjusting the pH to 6.0-6.5 with an acid selected from group comprising of hydrochloric acid, sulfuric acid, acetic acid; extracting into a solvent; adding one or more pharmaceutically acceptable carriers selected from group comprising of copovidone, hydroxypropyl methylcellulose, ethyl cellulose, polyethylene glycol, povidone or soluplus in a solvent at suitable temperature; and removing the solvent to obtain solid dispersion of Tafamidis in combination with a pharmaceutically acceptable carrier; wherein the process is carried out by not isolating Tafamidis free acid of Formula I.
  • a pharmaceutically acceptable carrier selected from group comprising of copovidone,
  • the present invention relates to Tafamidis salt of Formula IB which is organic or inorganic salt selected from group comprising of alkali, alkaline earth metal salts or amine salts; wherein alkali metal salts are selected from group comprising of Sodium and Potassium salts; alkaline earth metal salts selected from group comprising of Calcium and Magnesium salts; amines salts selected from group comprising of Triethanol amine, Triethyl amine, Meglumine, racemic (R)- and (S)- isomers of Phenyl ethyl amine, racemic, (R)- and (S)- isomers of Naphthyl ethyl amine, Cyclohexyl amine, Dicyclohexyl amine salts.
  • alkali metal salts are selected from group comprising of Sodium and Potassium salts
  • alkaline earth metal salts selected from group comprising of Calcium and Magnesium salts
  • amines salts selected from
  • the present invention relates to process for the preparation of Tafamidis salt of Formula IB which comprises: cyclizing the compound of Formula IV with acid selected from the group comprising of Methane sulfonic acid, Ethane sulfonic acid, p- Toluene sulfonic acid, Benzene sulfonic acid, Camphor sulfonic acid, D- Camphor sulfonic acid, L- Camphor sulfonic acid, pyridine sulfonic acid, polyphosphoric acid or acid anhydride selected from the group comprising of acetic anhydride, triflic anhydride; adding organic or inorganic base selected from group comprising of alkali bases selected from group comprising of Sodium and Potassium salts; alkaline earth metal bases selected from group comprising Calcium and Magnesium salts; amines selected from group comprising of Triethanol amine, Triethyl amine, Meglumine, racemic (R)- and (S)- isomers of
  • the present invention relates to process for the preparation of Tafamidis salt which comprises: treating Tafamidis free acid of Formula I with organic or inorganic base selected from group comprising of alkali bases selected from group comprising of Sodium and Potassium salts; alkaline earth metal bases selected from group comprising Calcium and Magnesium salts; amines selected from group comprising of Triethanol amine, Triethyl amine, Meglumine, racemic (R)- and (S)- isomers of Phenyl ethyl amine, racemic, (R)- and (S)- isomers of Naphthyl ethyl amine, Cyclohexyl amine, Dicyclohexyl amine in a solvent at suitable temperature; and isolating solid form of Tafamidis salt of Formula IB.
  • organic or inorganic base selected from group comprising of alkali bases selected from group comprising of Sodium and Potassium salts; alkaline earth metal bases selected from group compris
  • the present invention relates to crystalline form of compound of Formula IV which is characterized peaks by Powder X-Ray Diffraction, having the °20 characteristic peaks at 13.5, 15.5, 24.3+ 0.2 degrees and as depicted in Figure 1.
  • cyclizing of the compound of Formula IV is carried out in the presence of base selected from group comprising of triethylamine, tri n- butylamine, diisopropylethylamine, N-methylmorpholine, N-methylpiperidine, pyridine, picolines, lutidines, quinolone, isoquinolone, imidazole, benzimadazole, 1,2,4-triazole, 1,3,4-triazole, pyrazine, pyrimidine.
  • base selected from group comprising of triethylamine, tri n- butylamine, diisopropylethylamine, N-methylmorpholine, N-methylpiperidine, pyridine, picolines, lutidines, quinolone, isoquinolone, imidazole, benzimadazole, 1,2,4-triazole, 1,3,4-triazole, pyrazine, pyrimidine.
  • suitable temperature is the temperature at which the reaction proceeds and is in the range of room temperatures to reflux temperatures.
  • solvent used throughout the invention are selected from polar aprotic solvents, non-polar solvents, protic solvents selected from the group comprising of ketones, esters, nitriles, dimethyl sulfoxide, dimethyl formamide, halogenated hydrocarbons, water, alcohols, ethers, hydrocarbons.
  • ketones are aliphatic ketones selected from the group comprising acetone, diethyl ketone, methyl ethyl ketone, methyl isobutyl ketone, methyl propyl ketone, cyclobutanone, cyclopentanone, cyclohexanone or mixtures thereof; esters are aliphatic esters or aromatic esters wherein aliphatic esters are selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate or mixtures thereof; nitriles are selected from the group comprising of aliphatic nitriles such as C2-C8 nitrile; halogenated hydrocarbons are selected from methylene dichloride, ethylene dichloride, chloroform, carbon tetrachloride or mixtures thereof; alcohols used throughout the invention are selected from aliphatic alcohols selected from
  • removal of solvent is carried out by techniques well-known in the art, for example, by evaporation, filtration, distillation, or drying.
  • 4-amino-3-hydroxybenzoicacid (1.0 eq, LR) was dissolved at 20° C. in a mixture of tetrahydrofuran (19 L/kg) and water (1.9 L/Kg). 3,5-dichlorobenzoylchloride (1.3 equiv) was added as a tetrahydrofuran solution (1.9 L/kg) and the mixture stirred for at least 30 minutes at 20° C. Once the reaction was deemed complete by HPLC ( ⁇ 5% remaining 4- amino-3-hydroxybenzoicacid), triethylamine (1.2 equiv) was added and the mixture was heated to 35° C. and stirred for at least 90 minutes. The solvent was partially displaced with ethanol by constant level distillation until 5-15% THF remained.
  • 6-Carboxy-2-(3,5-dichlorophenyl)-benzoxazole free acid (2.5 g, 8.1 mmol) and 2-propanol (49 mL) were charged to a 100 mL jacketed, 2-neck round bottom flask with magnetic stirrer. The resulting slurry was warmed to 70° C. with stirring. Water (8.8 mL) was then charged. In a separate 15 mL round bottom flask a solution of N-methyl-D-glucamine (1.58 g, 8.1 mmol) in 5 mL water was prepared and dissolved with stirring. The aqueous N- methyl-D-glucamine solution was then transferred to the reaction flask over 2 min.
  • Tafamidis meglumine 100 gm was suspended in DM water (1000 ml) and adjusted the pH of the reaction mixture to 6.0 -6.5 with cone hydrochloric acid. Added Tetrahydrofuran (1500 ml) and heated the reaction mixture to 50-55°C, stirred for 10 - 15 minutes, separated the layers and filtered through micron filter. Added Copovidone (60 gm) to the filtrate and distilled off the solvent completely under vacuum to yield 115 gm Tafamidis solid dispersion with Copovidone.
  • Tafamidis (10 gm), Copovidone (10 gm) and tetrahydrofuran (200 ml) and heated the reaction mixture to 50 -55°C to obtain clear solution. Distilled off the reaction mixture completely under vacuum and dried to yield 20 gm of Tafamidis solid dispersion with Copovidone.
  • Tafamidis solid dispersion Charged Tafamidis (10 gm), Hydroxypropyl methylcellulose (6 gm) and tetrahydrofuran (200 ml) and heated the reaction mixture to 50 -55° C to obtain clear solution. Distilled off the reaction mixture completely under vacuum and dried to yield 16 gm of Tafamidis solid dispersion with Hydroxypropyl methylcellulose.

Abstract

La présente invention concerne une dispersion solide de tafamidis (acide libre) de formule (I) avec un support pharmaceutiquement acceptable, ainsi qu'un procédé de préparation du composé méglumine de tafamidis représenté par la formule (IA).
PCT/IB2020/057128 2019-08-01 2020-07-29 Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine WO2021019448A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941031097 2019-08-01
IN201941031097 2019-08-01

Publications (1)

Publication Number Publication Date
WO2021019448A1 true WO2021019448A1 (fr) 2021-02-04

Family

ID=74230217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/057128 WO2021019448A1 (fr) 2019-08-01 2020-07-29 Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine

Country Status (1)

Country Link
WO (1) WO2021019448A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113321627A (zh) * 2021-06-06 2021-08-31 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
CN113735792A (zh) * 2021-09-22 2021-12-03 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法
CN114907283A (zh) * 2021-02-07 2022-08-16 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (fr) 2021-04-26 2022-11-02 Química Sintética, S.A. Forme de tafamidis à l'état solide et son procédé de préparation
WO2022239020A1 (fr) * 2021-05-11 2022-11-17 Dr. Reddy’S Laboratories Limited Formes solides de tafamidis et leurs procédés de préparation
US11523993B1 (en) 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
WO2023171980A1 (fr) * 2022-03-10 2023-09-14 고려대학교 산학협력단 Nouveau procédé de synthèse de tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
KR102657823B1 (ko) 2022-03-10 2024-04-16 고려대학교 산학협력단 타파미디스의 신규 합성법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (fr) * 2002-12-19 2004-07-08 The Scripps Research Institute Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005113523A1 (fr) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
WO2013038351A1 (fr) * 2011-09-16 2013-03-21 Pfizer Inc. Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine
WO2013168014A1 (fr) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
US20190119226A1 (en) * 2016-05-05 2019-04-25 Crystal Pharmatech Co., Ltd. Crystalline form e of tafamidis meglumine, process for preparation and use thereof
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056315A2 (fr) * 2002-12-19 2004-07-08 The Scripps Research Institute Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005113523A1 (fr) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
WO2013038351A1 (fr) * 2011-09-16 2013-03-21 Pfizer Inc. Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine
WO2013168014A1 (fr) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
US20190119226A1 (en) * 2016-05-05 2019-04-25 Crystal Pharmatech Co., Ltd. Crystalline form e of tafamidis meglumine, process for preparation and use thereof
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHUONG TRAN ET AL.: "Overview of the Manufacturing Methods of Solid Dispersion Technology for Improving the Solubility of Poorly Water-Soluble Drugs and Application to Anticancer Drugs", PHARMACEUTICS, vol. 11, no. 13, 2019, pages 2, XP055707923, DOI: 10.3390/pharmaceutics11030132 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907283A (zh) * 2021-02-07 2022-08-16 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (fr) 2021-04-26 2022-11-02 Química Sintética, S.A. Forme de tafamidis à l'état solide et son procédé de préparation
WO2022239020A1 (fr) * 2021-05-11 2022-11-17 Dr. Reddy’S Laboratories Limited Formes solides de tafamidis et leurs procédés de préparation
CN113321627A (zh) * 2021-06-06 2021-08-31 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
CN113735792A (zh) * 2021-09-22 2021-12-03 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法
US11523993B1 (en) 2021-11-18 2022-12-13 Nuray Chemicals Private Limited Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof
WO2023171980A1 (fr) * 2022-03-10 2023-09-14 고려대학교 산학협력단 Nouveau procédé de synthèse de tafamidis
KR102657823B1 (ko) 2022-03-10 2024-04-16 고려대학교 산학협력단 타파미디스의 신규 합성법
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis

Similar Documents

Publication Publication Date Title
WO2021019448A1 (fr) Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine
CA2651353C (fr) Formes polymorphes de mesylate d'imatinib et procedes pour la preparation de nouvelles formes cristallines ainsi que de formes amorphes et de formes alpha
AU2002366383B2 (en) Polymorphs of clopidogrel hydrogensulfate
US7977348B2 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
RU2385325C2 (ru) Способ получения сульфата атазанавира
JP2011512396A (ja) 新規な多形およびその調製方法
KR20120139763A (ko) 랄테그라비어 염 및 이의 결정형
US20080167477A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
AU779931B2 (en) Novel processes for making- and a new crystalline form of- leflunomide
AU2017238918A1 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N- methylmethanamine salt
US9624207B2 (en) Polymorphs of azilsartan medoxomil
JP2020528064A (ja) Ｌｆａ−１拮抗薬リフィテグラストを調製および精製するためのプロセス
US8067421B2 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP3286168A1 (fr) Forme solide d'aprémilast et un procédé pour sa préparation
WO2015049698A2 (fr) Procédé pour le régorafénib
WO2012090221A1 (fr) Nouveaux sels d'imatinib
KR20160126697A (ko) 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
US20240010629A1 (en) Solid state form of lemborexant
JP2014504281A (ja) 酒石酸によるトリアジン誘導体エナンチオマーの分離
WO2022264072A1 (fr) Polymorphes d'acide 2-(3,5-dichlorophényl)-l,3-benzoxazole-6-carboxylique
WO2016206633A1 (fr) Composé de phénylamino pyrimidine ou polymorphe d'un sel de ce dernier
WO2023158772A1 (fr) Formes à l'état solide de danicopan et procédé associé
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib
EP1785411A1 (fr) Forme crystalline de proptriptyline hydrochloride
AU2005202109A1 (en) Novel processes for making- and a new crystalline form of- leflunomide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20846363

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20846363

Country of ref document: EP

Kind code of ref document: A1